Singapore markets closed

Cyclerion Therapeutics, Inc. (CYCN)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
3.1200-0.0300 (-0.95%)
At close: 04:00PM EDT
3.0000 -0.12 (-3.85%)
After hours: 07:48PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 7.80M
Enterprise value 2.10M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)55.50
Price/book (mrq)0.79
Enterprise value/revenue -655.82
Enterprise value/EBITDA 0.56

Trading information

Stock price history

Beta (5Y monthly) 1.92
52-week change 3-2.38%
S&P500 52-week change 318.96%
52-week high 35.2500
52-week low 31.7500
50-day moving average 32.7292
200-day moving average 32.9648

Share statistics

Avg vol (3-month) 35.25k
Avg vol (10-day) 38.09k
Shares outstanding 52.5M
Implied shares outstanding 62.7M
Float 81.21M
% held by insiders 121.90%
% held by institutions 140.53%
Shares short (15 Jul 2024) 417.3k
Short ratio (15 Jul 2024) 41.58
Short % of float (15 Jul 2024) 41.05%
Short % of shares outstanding (15 Jul 2024) 40.69%
Shares short (prior month 14 Jun 2024) 414.53k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 316 May 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-43.77%
Return on equity (ttm)-158.12%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-10.95M
Diluted EPS (ttm)-4.5500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)5.7M
Total cash per share (mrq)2.28
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)4.17
Book value per share (mrq)3.97

Cash flow statement

Operating cash flow (ttm)-16.9M
Levered free cash flow (ttm)-9.41M